Takeda Pharmaceutical (TAK) Cash & Current Investments (2017 - 2026)

Takeda Pharmaceutical has reported Cash & Current Investments for 10 years, with the latest figure at $5.8 billion in Q2 2026.

• On a quarterly basis, Cash & Current Investments rose 22.08% year-over-year to $5.8 billion in Q2 2026; TTM through Jun 2026 was $5.8 billion, a 22.08% increase from a year earlier, with the FY2026 full-year figure at $6.6 billion, up 36.55% from the prior year.
• Cash & Current Investments was $5.8 billion for Q2 2026 at Takeda Pharmaceutical, down from $6.6 billion in the prior quarter.
• The five-year high for Cash & Current Investments was $9.3 billion in Q1 2022, with the low at $3.8 billion in Q4 2023.
• Average Cash & Current Investments over 5 years is $6.3 billion, with a median of $6.4 billion recorded in 2023.
• The sharpest annual moves came in 2023 and 2024: Cash & Current Investments plunged 46.43% in 2023, then soared 71.87% in 2024.
• Over 5 years, Cash & Current Investments stood at $6.8 billion in 2022, then sank by 44.46% to $3.8 billion in 2023, then jumped by 55.37% to $5.9 billion in 2024, then increased by 19.53% to $7.0 billion in 2025, then decreased by 17.3% to $5.8 billion in 2026.
• The last three Cash & Current Investments figures came in at $5.8 billion (Q2 2026), $6.6 billion (Q1 2026), and $7.0 billion (Q4 2025), per Business Quant data.